Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

PLSE

Pulse Biosciences (PLSE)

Pulse Biosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PLSE
DateTimeSourceHeadlineSymbolCompany
16/05/202422:00Business WirePulse Biosciences’ CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual MeetingNASDAQ:PLSEPulse Biosciences Inc
15/05/202423:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PLSEPulse Biosciences Inc
15/05/202406:05Business WirePulse Biosciences Enhances Executive Leadership TeamNASDAQ:PLSEPulse Biosciences Inc
09/05/202423:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PLSEPulse Biosciences Inc
09/05/202422:00Business WirePulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode SystemNASDAQ:PLSEPulse Biosciences Inc
08/05/202406:18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PLSEPulse Biosciences Inc
08/05/202406:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PLSEPulse Biosciences Inc
08/05/202406:05Business WirePulse Biosciences Reports Business Updates and First Quarter 2024 Financial ResultsNASDAQ:PLSEPulse Biosciences Inc
02/05/202422:00Business WirePulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000NASDAQ:PLSEPulse Biosciences Inc
25/04/202406:05Business WirePulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024NASDAQ:PLSEPulse Biosciences Inc
29/03/202407:12Business WirePulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial ResultsNASDAQ:PLSEPulse Biosciences Inc
29/03/202407:10Business WirePulse Biosciences Announces Plans to Initiate a Rights OfferingNASDAQ:PLSEPulse Biosciences Inc
15/03/202407:05Business WirePulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024NASDAQ:PLSEPulse Biosciences Inc
12/03/202400:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PLSEPulse Biosciences Inc
09/03/202405:17Business WirePulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode SystemNASDAQ:PLSEPulse Biosciences Inc
15/02/202401:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PLSEPulse Biosciences Inc
15/02/202400:00Business WirePulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility StudyNASDAQ:PLSEPulse Biosciences Inc
01/02/202400:00Business WirePulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF SymposiumNASDAQ:PLSEPulse Biosciences Inc
10/01/202401:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PLSEPulse Biosciences Inc
03/01/202401:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PLSEPulse Biosciences Inc
03/01/202400:00Business WirePulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac ClampNASDAQ:PLSEPulse Biosciences Inc
23/12/202301:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PLSEPulse Biosciences Inc
21/12/202301:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PLSEPulse Biosciences Inc
21/12/202300:00Business WirePulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac CatheterNASDAQ:PLSEPulse Biosciences Inc
28/11/202309:29Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:PLSEPulse Biosciences Inc
28/11/202301:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PLSEPulse Biosciences Inc
22/11/202301:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PLSEPulse Biosciences Inc
22/11/202300:00Business WirePulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous ElectrodeNASDAQ:PLSEPulse Biosciences Inc
18/11/202301:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PLSEPulse Biosciences Inc
18/11/202301:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PLSEPulse Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:PLSE